Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD
Treatment with ruxolitinib led to prolonged failure-free survival and improved disease control vs best available treatment in patients with either steroid-refractory or -dependent chronic graft-vs-host disease.
Robert Zeiser Center At University Of Freiburg Medical Center Patients With Chronic Graft Versus Host Disease Year Final Analysis Safety From
Source: onclive.com